For the second quarter NeoGenomics reported earnings of 2 cent a share, in line with the Capital IQ Consensus Estimate. Revenue grew 32.7% from the year-ago quarter to $20.7 million, above analysts' estimates of $20.12 million.
Looking to the third quarter NeoGenomics expects earnings of between a loss of 1 cent and a 1 cent a share while analysts expect the company to break even for the quarter. The company expects revenue of $22 million to $23.5 million in the third quarter, about analysts' expectations of $21.6 million.
Must read: Warren Buffett's 25 Favorite Stocks